Aarhus University Seal / Aarhus Universitets segl

Annette de Thurah

Methotrexatbehandling af rheumatoid artritis i Danmark

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

In the recommended early, aggressive and continuous treatment strategy of rheumatoid arthritis (RA), methotrexate (MTX) is the anchor drug, and although generally well tolerated approximately 50% of the RA patients discontinue MTX treatment within five years. In a large Danish cohort study among newly diagnosed patients with RA only 21% had started MTX treatment within 90 days after referral to hospital and the median time-to-treatment initiation was 120 days. Furthermore, MTX compliance is considered generally high among Danish RA patients and the patients have strong beliefs about MTX necessity.
Bidragets oversatte titel[Methotrexate treatment of rheumatoid arthritis in Denmark.]
TidsskriftUgeskrift for Laeger
Sider (fra-til)2187-2189
Antal sider3
StatusUdgivet - 5 sep. 2011

Se relationer på Aarhus Universitet Citationsformater

ID: 40446582